Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Patience

<< Previous

Bullboard Posts

Next >>

Comment by YanTheDonon Jul 20, 2018 11:10am

55 Views

Post# 28344403

RE:RE:RE:RE:RE:Patience

bootsncats wrote: It's an antifungal. It treats Aspergillosis infection, which is a serious and deadly infection. Treatment for this can take upwards to 11 months.
Furthermore, there are other indications for amphoteracin B. And to get approval for these indications (ie. other microbes), they have to test it for those microbes as well.

This website is cancer. So many trolls and immature ppl on here. For the life of me, I can't understand who and why anyone would give this post a 1-star rating.
I wish there was a way to monitor and block these trolls.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market